Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes: The WhyTrace cohort study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes : The WhyTrace cohort study. / Vesterlund, Gitte K.; Thorsen-Meyer, Hans Christian; Møller, Morten H.; Brunak, Søren; Strøm, Thomas; Perner, Anders; Kaas-Hansen, Benjamin S.

In: Acta Anaesthesiologica Scandinavica, Vol. 67, No. 7, 2023, p. 925-935.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Vesterlund, GK, Thorsen-Meyer, HC, Møller, MH, Brunak, S, Strøm, T, Perner, A & Kaas-Hansen, BS 2023, 'Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes: The WhyTrace cohort study', Acta Anaesthesiologica Scandinavica, vol. 67, no. 7, pp. 925-935. https://doi.org/10.1111/aas.14247

APA

Vesterlund, G. K., Thorsen-Meyer, H. C., Møller, M. H., Brunak, S., Strøm, T., Perner, A., & Kaas-Hansen, B. S. (2023). Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes: The WhyTrace cohort study. Acta Anaesthesiologica Scandinavica, 67(7), 925-935. https://doi.org/10.1111/aas.14247

Vancouver

Vesterlund GK, Thorsen-Meyer HC, Møller MH, Brunak S, Strøm T, Perner A et al. Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes: The WhyTrace cohort study. Acta Anaesthesiologica Scandinavica. 2023;67(7):925-935. https://doi.org/10.1111/aas.14247

Author

Vesterlund, Gitte K. ; Thorsen-Meyer, Hans Christian ; Møller, Morten H. ; Brunak, Søren ; Strøm, Thomas ; Perner, Anders ; Kaas-Hansen, Benjamin S. / Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes : The WhyTrace cohort study. In: Acta Anaesthesiologica Scandinavica. 2023 ; Vol. 67, No. 7. pp. 925-935.

Bibtex

@article{15fef877e5b2401baf749a83d654e328,
title = "Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes: The WhyTrace cohort study",
abstract = "Background: Abnormal serum levels of magnesium, phosphate, and zinc appear common in intensive care unit (ICU) patients, but the epidemiology, management, and associations with outcomes are less well described. We described these factors and estimated associations with outcomes in a large dataset of Danish ICU patients. Methods: We included adults who were acutely admitted to 10 general ICUs in Denmark between October 2011 and January 2018. From the dataset, we obtained characteristics of patients who had serum levels measured of magnesium, phosphate, or zinc, including data on supplementation. We used joint models with death as a competing outcome to estimate the associations between abnormal serum levels and time to successful extubation and, for magnesium, also incident tachyarrhythmia. Results: We included 16,517 of 36,514 patients in the dataset. The cumulative probability of hypomagnesemia within 28 days was 64% (95% confidence interval [CI] 62–66); of hypophosphatemia 74% (95% CI 72–75); and of hypozincemia 98% (95% CI 98–98). Supplementation of magnesium was used in 3554 out of 13,506 (26%) patients, phosphate in 2115 out of 14,148 (15%) patients, and zinc in 4465 out of 9869 (45%) patients. During ICU stay, 38% experienced hypermagnesemia, 58% hyperphosphatemia, and 1% hyperzincemia. Low serum levels of magnesium, phosphate, and zinc were associated with shorter time to successful extubation, and high serum magnesium and phosphate and low serum zinc with the competing risk of increased mortality, but too few serum measurements made the results inconclusive. Conclusion: In this multicenter cohort study of acutely admitted ICU patients, most experienced low serum levels of magnesium, phosphate, or zinc during ICU stay, many received supplementation, and experiencing both low and high serum levels during ICU stay was not uncommon. Associations between serum levels and clinical outcomes appeared inconclusive because the data proved unfit for these analyses.",
keywords = "cohort, critically ill, ICU, magnesium, phosphate, zinc",
author = "Vesterlund, {Gitte K.} and Thorsen-Meyer, {Hans Christian} and M{\o}ller, {Morten H.} and S{\o}ren Brunak and Thomas Str{\o}m and Anders Perner and Kaas-Hansen, {Benjamin S.}",
note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.",
year = "2023",
doi = "10.1111/aas.14247",
language = "English",
volume = "67",
pages = "925--935",
journal = "Acta Anaesthesiologica Scandinavica",
issn = "0001-5172",
publisher = "Wiley-Blackwell",
number = "7",

}

RIS

TY - JOUR

T1 - Abnormal serum levels of magnesium, phosphate, and zinc in ICU patients—Characteristics, management, and outcomes

T2 - The WhyTrace cohort study

AU - Vesterlund, Gitte K.

AU - Thorsen-Meyer, Hans Christian

AU - Møller, Morten H.

AU - Brunak, Søren

AU - Strøm, Thomas

AU - Perner, Anders

AU - Kaas-Hansen, Benjamin S.

N1 - Publisher Copyright: © 2023 The Authors. Acta Anaesthesiologica Scandinavica published by John Wiley & Sons Ltd on behalf of Acta Anaesthesiologica Scandinavica Foundation.

PY - 2023

Y1 - 2023

N2 - Background: Abnormal serum levels of magnesium, phosphate, and zinc appear common in intensive care unit (ICU) patients, but the epidemiology, management, and associations with outcomes are less well described. We described these factors and estimated associations with outcomes in a large dataset of Danish ICU patients. Methods: We included adults who were acutely admitted to 10 general ICUs in Denmark between October 2011 and January 2018. From the dataset, we obtained characteristics of patients who had serum levels measured of magnesium, phosphate, or zinc, including data on supplementation. We used joint models with death as a competing outcome to estimate the associations between abnormal serum levels and time to successful extubation and, for magnesium, also incident tachyarrhythmia. Results: We included 16,517 of 36,514 patients in the dataset. The cumulative probability of hypomagnesemia within 28 days was 64% (95% confidence interval [CI] 62–66); of hypophosphatemia 74% (95% CI 72–75); and of hypozincemia 98% (95% CI 98–98). Supplementation of magnesium was used in 3554 out of 13,506 (26%) patients, phosphate in 2115 out of 14,148 (15%) patients, and zinc in 4465 out of 9869 (45%) patients. During ICU stay, 38% experienced hypermagnesemia, 58% hyperphosphatemia, and 1% hyperzincemia. Low serum levels of magnesium, phosphate, and zinc were associated with shorter time to successful extubation, and high serum magnesium and phosphate and low serum zinc with the competing risk of increased mortality, but too few serum measurements made the results inconclusive. Conclusion: In this multicenter cohort study of acutely admitted ICU patients, most experienced low serum levels of magnesium, phosphate, or zinc during ICU stay, many received supplementation, and experiencing both low and high serum levels during ICU stay was not uncommon. Associations between serum levels and clinical outcomes appeared inconclusive because the data proved unfit for these analyses.

AB - Background: Abnormal serum levels of magnesium, phosphate, and zinc appear common in intensive care unit (ICU) patients, but the epidemiology, management, and associations with outcomes are less well described. We described these factors and estimated associations with outcomes in a large dataset of Danish ICU patients. Methods: We included adults who were acutely admitted to 10 general ICUs in Denmark between October 2011 and January 2018. From the dataset, we obtained characteristics of patients who had serum levels measured of magnesium, phosphate, or zinc, including data on supplementation. We used joint models with death as a competing outcome to estimate the associations between abnormal serum levels and time to successful extubation and, for magnesium, also incident tachyarrhythmia. Results: We included 16,517 of 36,514 patients in the dataset. The cumulative probability of hypomagnesemia within 28 days was 64% (95% confidence interval [CI] 62–66); of hypophosphatemia 74% (95% CI 72–75); and of hypozincemia 98% (95% CI 98–98). Supplementation of magnesium was used in 3554 out of 13,506 (26%) patients, phosphate in 2115 out of 14,148 (15%) patients, and zinc in 4465 out of 9869 (45%) patients. During ICU stay, 38% experienced hypermagnesemia, 58% hyperphosphatemia, and 1% hyperzincemia. Low serum levels of magnesium, phosphate, and zinc were associated with shorter time to successful extubation, and high serum magnesium and phosphate and low serum zinc with the competing risk of increased mortality, but too few serum measurements made the results inconclusive. Conclusion: In this multicenter cohort study of acutely admitted ICU patients, most experienced low serum levels of magnesium, phosphate, or zinc during ICU stay, many received supplementation, and experiencing both low and high serum levels during ICU stay was not uncommon. Associations between serum levels and clinical outcomes appeared inconclusive because the data proved unfit for these analyses.

KW - cohort

KW - critically ill

KW - ICU

KW - magnesium

KW - phosphate

KW - zinc

U2 - 10.1111/aas.14247

DO - 10.1111/aas.14247

M3 - Journal article

C2 - 37078441

AN - SCOPUS:85153523656

VL - 67

SP - 925

EP - 935

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 7

ER -

ID: 345644615